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PURPOSE. To evaluate the antilymphangiogenic potential of multi-target tyrosine kinase
inhibitor sunitinib in corneal neovascularization (NV).
METHODS. Inflammatory corneal NV was induced by thermal cauterization applied in the
central cornea of mice, to which sunitinib malate was daily administered by gavage or not. At
days 6, 11, or 17 post cauterization, lymphatic and blood vessels, as well as inflammatory cells
were immunostained and quantified in whole-mounted corneas. RT-PCRs were performed to
evidence VEGF–A, VEGF-C, VEGF-D, placental growth factor (PlGF), and soluble vascular
endothelial growth factor receptor (VEGFR)-1 and -2 (sVEGFR-1, sVEGFR-2) expressions.
Macrophages were isolated from mice peritoneal cavity following thioglycollate injection to
produce conditioned medium. The effects of sunitinib were evaluated in vitro in the aortic
and lymphatic ring assays in the presence or not of macrophage conditioned medium.
RESULTS. Sunitinib treatment drastically reduced pathologic corneal lymphangiogenesis and
angiogenesis. Reduced F4/80þ cell infiltration was evidenced in sunitinib-treated mice and
was associated to decreased VEGF-A (by 50%, P < 0.01) and VEGF-C (by 35%, P < 0.01)
expressions, while VEGF-D and sVEGFR-2 expressions were not affected. In vitro, sunitinib
dose-dependently inhibited aortic ring outgrowth, but failed to affect lymphangiogenesis in
the lymphatic ring assay. However, macrophage conditioned medium-enhanced angiogenesis
and lymphangiogenesis were both strongly counteracted by sunitinib treatment. Mechanis-
tically, sunitinib blocked VEGFR-2 phosphorylation induced by VEGF-A released by
macrophages.
CONCLUSIONS. Sunitinib exerts antihemangiogenic and antilymphangiogenic effects in vivo by
reducing F4/80þ cell recruitment and interacting with their released factors.
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The avascularity of the cornea is actively maintained inhealthy conditions and is necessary to preserve cornea
transparency and optimal visual acuity.1 This ‘‘angiogenic
privilege’’ relies on the production of antilymph/angiogenic
factors such as soluble forms of vascular endothelial growth
factor receptor (sVEGFR-1, sVEGFR-2),2–4 thrombospondins,5
angiostatin, endostatin, and pigmented epithelium derived
factor,6 counterbalancing the basal expression of prolymph/
angiogenic factors (e.g., VEGF-A).1 The avascular cornea can
secondarily be invaded by blood vessels (hemangiogenesis)
and/or lymphatic vessels (lymphangiogenesis) under severe
inflammation. Thus, such a corneal neovascularization (NV)
can occur in several pathologic conditions such as hypoxia,
infections (e.g., Herpes Simplex Virus, Chlamydia trachoma-
tis), trauma, or keratoplasty, leading to reduced visual acuity.7
NV, in particular lymphangiogenesis, is also the major factor
leading to cornea graft rejection occurring after keratoplasty.8
The VEGF family members are generally considered as the
main regulators of lymph/angiogenesis through the binding to
their receptors, the VEGFRs. Among them, VEGF-A enhances
hemangiogenesis through VEGFR-2 binding, expressed by
blood endothelial cells. VEGF-C and -D are the main prolym-
phangiogenic factors that act through the activation of VEGFR-3
expressed on lymphatic endothelial cells (LECs). However,
LECs also express VEGFR-2 and processed forms of VEGF-C and
VEGF-D are also able to bind VEGFR-2, demonstrating
interconnections between the two pathways.9 VEGF-A–medi-
ated corneal NV has been attributed to the stimulation of both
hemangiogenesis and lymphangiogenesis,7,10 directly11 or
indirectly by recruiting inflammatory cells able to deliver
VEGF-C and -D.12
Strategies aiming at blocking VEGF pathway have been
developed to inhibit lymph/angiogenesis, and notably consist of
anti–VEGF-A antibodies and aptamers (bevacizumab, ranibizu-
mab, pegaptanib) or small molecules designed to inhibit the
tyrosine kinase activity of VEGFRs (sunitinib, sorafenib,
vatalanib, etc.). Although bevacizumab was approved by Food
and Drug Administration (FDA) for cancer and AMD treat-
ment,13 and several molecules including anti-VEGF antibodies
and tyrosine kinase inhibitors have been demonstrated to
efficiently inhibit corneal NV in mice models,14–16 no treatment
specifically targeting lymph/angiogenesis is available to treat
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corneal NV.7 Corneal NV is currently treated with corticoste-
roids, which control inflammatory reaction and display
antilymph/angiogenic properties, but their effects are limited
and are associated to adverse effects.7,17
In the present work, we evaluated the impact of sunitinib
on corneal NV. Sunitinib is a multi-target tyrosine kinase
inhibitor able to inhibit VEGFRs, platelet-derived growth factor
receptor (PDGFR), c-kit and ret, and has already been approved
by FDA for the treatment of metastasic renal cell carcinomas
and gastro intestinal stromal tumors that are resistant to
imatinib.18 Although antiangiogenic effects of sunitinib
through VEGFR-2 inhibition is well recognized, and has been
shown in rabbit corneas,19 its effect on lymphangiogenesis
remains unclear. Kodera and colleagues recently demonstrated
sunitinib-inhibited lymphangiogenesis in a murine model of
breast cancer through VEGFR-3 inhibition.20 However, wheth-
er sunitinib is or is not a potent inhibitor of corneal
lymphangiogenesis is still unknown. We demonstrate here that
sunitinib exerts in vivo earlier and stronger inhibitory effects
on corneal lymphangiogenesis than on hemangiogenesis.
These inhibitory effects are associated with reduced F4/80þ
cell recruitment. In vitro studies underscore an indirect effect
on lymphangiogenesis through the interference with lymphan-
giogenic factors released by macrophages.
MATERIALS AND METHODS
Mice
Six-week-old male C57BL/6 mice purchased from Janvier (Saint
Berthevin, France) were used throughout this study. The
animals were maintained with a 12 hour light-dark cycle and
had free access to food and water. Animal experiments were
performed in compliance with the Animal Ethical Committee
of the University of Lie`ge (Lie`ge, Belgium) and in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research.
Sunitinib
Sunitinib malate (SU-11248) was purchased from LC Laborato-
ries (Woburn, MA). For in vivo assays, sunitinib was solubilized
in 0.5% carboxymethylcellulose and 40 mg/kg were daily
administered by oral gavage. Control mice received vehicle. For
in vitro assays, sunitinib was solubilized in dimethyl sulfoxide
(DMSO) and used at 20 nM in culture medium containing 0.1%
DMSO.
Corneal Neovascularization Assay and
Immunostainings
Corneal NV was induced by thermal cauterization as previously
described.21–23 After anesthetizing the mouse with intraperi-
toneal injection of ketamine hydrochloride (100 mg/kg body
weight) and xylazine (10 mg/kg body weight), the anesthetized
central cornea (Unica¨ıne 0.4%; Thea Pharma, Wetteren,
Belgium) was thermally cauterized using an ophthalmic
cautery (Optemp II V; Alcon Surgical, Fort Worth, TX). Mice
were time course sacrificed and eyes were removed and
dissected. Whole-mounted corneas were fixed in 70% ethanol
for 1 hour at room temperature and blocked in 3% BSA–3%
Gloria milk (Nestle´, Brussels, Belgium) for 1 hour.
For double lymphatic vessel endothelial hyaluronan recep-
tor-1 (LYVE-1) and CD31 immunostainings, corneas were
incubated overnight with polyclonal goat antimouse LYVE-1
(1/200; R&D Systems, Abingdon, UK) and rat antimouse CD31
(1/200; BD Biosciences Pharmingen, San Jose, CA). Then
incubations with Alexa Fluor 488–coupled rabbit antigoat
antibody (1/200; Molecular Probes, Merelbeke, Belgium) and
Alexa Fluor 546–coupled goat antirat (1/200; Molecular
Probes) were performed for 2 hours. For double LYVE-1–
CD11b or F4/80 immunostainings, corneas were incubated
overnight with polyclonal goat antimouse LYVE-1 and biotin-
coupled rat antimouse CD11b (1/250; BD Biosciences) or rat
antimouse F4/80 (1/100; Abcam, Cambridge, UK). Alexa Fluor
488–coupled rabbit antigoat antibody (1/200; Molecular
Probes) and biotin-coupled rabbit antirat immunoglobulin (1/
400; Dako, Glostrup, Denmark) were added for 2 hours,
followed by 2 hours incubation with Alexa Fluor 555–coupled
streptavidin (1/500; Molecular Probes).
Corneas flat-mounted on a microscope slide with Vecta-
shield mounting medium (Vector Laboratories, Burlingame,
CA) were examined with a fluorescent microscope (AH3-
RFCA; Olympus, Hamburg, Germany). Pictures were taken at
340 magnification and assembled to reconstitute the whole
cornea picture with Microsoft Image Composite Editor (Micro-
soft Corporation, Santa Rosa, CA).
Computerized Methods of Quantification
The previously described computerized quantification method
of lymphatic network developing in the cornea was extended
to blood vessels.21 Image processing algorithms were first
developed in order to extract blood and lymphatic vessels from
the background. This resulted in two independent binary
images, in which lymphatic and blood vessels were represent-
ed by white pixels (pixels value equal to 1) on a black
background (pixels value equal to 0). After binarization, the
following automatic measurements were performed: (1) area
density defined as the surface covered by vessels reported to
total cornea area; (2) end point density defined as the number
of vessel extremities per corneal area unit (this parameter
indicates the increase/decrease of sprout tips); (3) branching
density, defined as the number of vessel branchings per corneal
area unit, which indicates the structure degree of complexity;
(4) length density, which represents the cumulative length of
vessels; (5) maximal length of vessels, which indicates the
largest migration distance; and (6) spatial distribution of vessels
in relation to the limbal vessel. This distribution gives local
information about the number of vessels at each given position
in relation to the limbal vessel.
For inflammatory cell quantification (red labeling), the
contrast was first enhanced on original red(R)-green(G)-blue(B)
color image by combining color components as 2R-G-B images.
Heterogeneous illumination was further corrected using a
morphological tool (top-hat transformation).24 Finally, an
automatic threshold maximizing the global average contrast
across the picture25 was applied to obtain a binary image with
intensity 1 and 0, respectively for inflammatory cells and
background. A 0.8-mm thick ring, comprised between the edge
of the limbus and the center of the cornea, was arbitrary
defined to eliminate unspecific staining present in the center of
the cornea and resulting from cauterization. Cell density was
calculated as the ratio of pixels belonging to inflammatory cells
and the total ring area.
Image processing and measurements were performed using
Aphelion 3.2 software (Adcis, Saint-Contest, France) and image
analysis toolbox of Matlab 7.9 software (The Mathworks, Inc.,
Natick, MA).
Macrophage Culture
Peritoneal lavage was performed to isolate primary macro-
phages from C57BL/6 mice intraperitoneally injected with 4%
thioglycollate (T-9032; Sigma-Aldrich, St. Louis, MO) 5 days
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earlier. Cells were cultured in serum-free RPMI-1640 (Lonza,
Braine-l’Alleud, Belgium) for 1 hour at 378C. Non adherent cells
were removed by 5 PBS washes.26 Adherent cells were
cultured for 24 hours in serum-free RPMI-1640 before
collecting conditioned medium. More than 80% macrophages
were identified on cytospins.
Aortic (ARA) and Lymphatic Ring Assays (LRA)
Three-dimensional (3D) aortic or lymphatic ring cultures were
performed as described previously.27–29 Briefly, aorta dissected
from Wistar rats or thoracic duct dissected from C57BL/6 mice
were cut into small fragments. The explants were embedded in
interstitial type I collagen gel (1.5 mg/mL; Serva, Heidelberg,
Germany) and cultured in MCDB131 (Invitrogen, Merelbeke,
Belgium). For lymphatic ring assay, medium was supplemented
with 2% Ultroser G (BioSepra, Cergy Saint Christophe, France)
and explants were cultured under hypoxic conditions (5% O2,
5% CO2, and 90% N2). In some conditions, 20 nM sunitinib (LC
Laboratories, Woburn, MA) or 10% macrophage conditioned
medium was added to culture medium. VEGF-A (20 ng/mL;
Peprotech, London, UK) was used as positive control in the
aortic ring assays. Pictures were taken at the indicated times
(6–13 days) and computerized quantifications were performed
on binary images as described previously.29,30 Briefly, a grid
comprised of concentric rings was generated by successive
increments at fixed intervals of explant boundary. Then, the
number of microvessel grid intersections was counted and
plotted versus the distance from the ring to determine
microvessel distribution. At least five images per experimental
condition were used.
Reverse Transcription–Polymerase Chain Reaction
Frozen corneas were pulverized (MagNA Lyser; Roche, Indian-
apolis, IN) and total RNA was extracted with a kit (RNeasy;
Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. Cultured cells were washed with cold PBS and total
RNA was extracted with a kit (Roche, Indianapolis, IN)
according to the manufacturer’s protocol. VEGF-A, VEGF-C,
VEGF-D, placental growth factor (PlGF), sVEGFR-1, sVEGFR-2,
and glyceraldehyde-3-phosphate deshydrogenase (GAPDH)
mRNA were amplified with a 10-ng aliquot of total RNA using
an amplification kit (GeneAmp Thermostable rTth Reverse
Transcriptase RNA PCR Kit; Roche, Branchburg, Germany).
Reverse transcription was performed at 708C for 15 minutes
followed by RNA–DNA heteroduplexe denaturation at 948C.
Amplification started by a 20 second cycle at 948C, 20 seconds
at hybridation temperature, and finally 20 seconds at 728C. RT-
PCR products were resolved in 10% acrylamide gels after
staining with Gel Star (Cambrex, East Rutherford, NJ). The
primer sequences, hybridation temperatures, number of
cycles, and the length of the RT-PCR products are described
in the Table.
Endothelial Cell Culture and Western Blotting
LECs purchased from Lonza (HMVEC-dLy; Braine-l’Alleud,
Belgium) were cultured in endothelial growth medium
microvascular (EGM2-MV) medium (Lonza) supplemented
with 5% fetal calf serum (FCS) and L-glutamine (Invitrogen)
until confluence was reached. Cells were then rinsed with PBS
and placed for 24 hours in endothelial basal medium (EBM2)
serum-free medium (Lonza). Medium was then replaced by
EBM2 containing 20 nM sunitinib or 0.1% DMSO for 2 hours,
and cells were stimulated with 10% macrophage conditioned
medium for 10 minutes. In some samples, macrophage
conditioned medium was preincubated for 1 hour with 500
ng/mL sVEGFR-1 or sVEGFR-3 (R&D Systems) to trap VEGF-A
or VEGF-C and -D, respectively. Cells were rinsed with ice cold
PBS and lysed with radioimmunoprecipitation assay (RIPA)
buffer containing phosphatase and protease inhibitors (Roche,
Vilvoorde, Belgium). Samples were dissolved in SDS buffer and
migrated on 12% SDS-PAGE gel before being transferred onto a
polyvinyl difluoride (PVDF) membrane. After 1 hour blocking
in 1% casein, phosphorylated, and total proteins were detected
by 48C overnight incubation with the respective antibodies,
followed by 1 hour room temperature incubation in HRP-
coupled secondary antibody (Cell Signaling, San Diego, CA)
and ECL revelation in LAS4000 imager (Fujifilm, Tokyo, Japan).
The following antibodies were used: rabbit monoclonal
antiphospho-Akt, Akt, phospho-ERK1/2, ERK1/2, phospho–
VEGFR-2 and VEGFR-2 (Cell Signaling).
Proliferation and Tubulogenesis Assay
For proliferation assay, 43 103 LECs (HMVEC-dLy; Lonza) were
seeded in wells of 96-well plate and were grown overnight in
EGM2-MV medium (Lonza). Medium was then replaced by
serum-free EBM2 medium (Lonza) for 2 hours and cells were
stimulated with 50% macrophage conditioned medium for 48
hours containing 20 nM sunitinib or not. In some samples,
macrophage conditioned medium was preincubated for 1 hour
with 1 lg/mL sVEGFR-1 or sVEGFR-3 (R&D Systems) to trap
VEGF-A or VEGF-C and -D, respectively. Cell proliferation was
TABLE. Sequences of Primers Used for RT-PCR Experiments
Gene Primer Sequence Hybrid. Temperature Cycles Length
VEGF-A Sense: 50 -CCTGGTGGACATCTTCCAGGAGTA-30 668C 25 275 bp
Anti-sense: 50-CTCACCGCCTCCTGTCACA-30
VEGF-C Sense: 50 -GTAAAAACAAACTTTTCCCTAATTC-30 608C 30 161 bp
Anti-sense: 50-TTTAAGGAAGCACTTCTGTGTGT-30
VEGF-D Sense: 50 -GGTTGTCTTCCCCAGCTC-30 558C 30 129 bp
Anti-sense: 50-TCTCGCTCAGCATCCCATC-30
PlGF Sense: 50 -AGATCTTGAAGATTCCCCCCA-30 588C 33 130 bp
Anti-sense: 50-TTCCCCTTGGTTTTCCTCCTT-30
sVEGFR-1 Sense: 50 -AGGTGAGCACTGCGGCA-30 608C 28 106 bp
Anti-sense: 50-ATGAGTCCTTTAATGTTTGAC-30
sVEGFR-2 Sense: 50 -CACCAGTTTGCAAGAACTTGGATGCT-30 628C 26 218 bp
Anti-sense: 50-AATTCTGTCACCCAGGGATGC-30
GAPDH Sense: 50 -GCTGCCATTTGCAGTGGCAAAGT-30 668C 21 247 bp
Anti-sense: 50-GTGAAGACACCAGTAGACTCCAC-30
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then assessed using WST-1 proliferation kit (Roche, Indian-
apolis, IN) according to the manufacturer’s protocol.
For tubulogenesis assay, 33105 LECs were seeded on a type
I collagen layer (1 mg/ml, Collagen R; Serva Electrophoresis,
Heidelberg, Germany) in a 12-well plate. Cells were grown for
24 hours in EGM2-MV medium. Medium was then removed and
a second layer of collagen was added over the cells. Finally,
collagen-embedded LECs were incubated in 500 lL of serum-
free EBM2 medium containing or not 50% macrophage
conditioned medium and/or 20 nM sunitinib. After 6 hours,
five pictures per well were captured with a phase-contrast
microscope (Axiovert 25; Carl Zeiss Microscopy, Zaventem,
Belgium) coupled to an Axiocam color digital camera (Carl
Zeiss) and tube length was measured.
RESULTS
Time Course Corneal Lymph/Angiogenesis
Corneal NV was induced in C57BL/6 mice by thermal
cauterization. Mice were time course sacrificed to concomi-
tantly evaluate the progression of blood and lymphatic
networks developing in the cornea by double LYVE-1–CD31
immunostaining on whole-mounts (Fig. 1A). In healthy corneas
(Day 0), blood and lymphatic vessels were restricted to the
limbus but some lymphatics extended in the cornea as
previously described.31 Three days after cauterization, signif-
icant hemangiogenesis was observed that persisted until day
21. This was followed by a strong blood vessel regression
observed after 40 days. The lymphangiogenic process took
place more slowly with some short sproutings appearing on
lymphatic vessels at day 3 (Fig. 1A). Lymphatic vessels strongly
expanded between days 7 and 21. Lymphatic vessel regression
occurred in a lesser extent than the blood vessel ones. A
significant number of lymphatic vessels were still observed in
the center of corneas after 40 days (Fig. 1A). These vascular
changes were quantified through an original computerized
method (Fig. 1B), and objectivized through four parameters:
area density, length density, branching density, and end point
(sprout tip) density. Regarding hemangiogenesis, all these
parameters evidenced a linear and rapid blood vessel growth
that occurred until day 21 and was followed by a strong
regression leading to a bell shape curve. A latency phase of 5 to
7 days was observed for lymphangiogenesis, followed by a
rapid growth of lymphatic vessels, and finally, a regression
phase (Figs. 1C–F). The number of lymphatic vessels being far
inferior to blood vessel ones, lymphatic area density and length
density were much lower than blood vessel densities. Beside
area and length densities that provide an overall information on
blood and lymphatic vessel growth (Figs. 1C, 1D), branching
and end point densities give quantitative information about the
complexity of these vascular networks (Figs. 1E, 1F). This
quantification underlines that blood vessels presented much
more branchings and end points than lymphatics reflecting a
much more complex and ramified plexus.
Sunitinib Inhibits Both Corneal Hemangiogenesis
and Lymphangiogenesis
Corneal NV was induced in mice administered with 40 mg/kg
sunitinib by daily oral gavage. Mice were sacrificed 6, 11, or 17
days after cauterization and corneas were immunostained for
LYVE-1 and CD31. At early time points (days 6 and 11),
sunitinib did not inhibit the sprouting of blood vessels and
similar number of end points and branchings were observed in
the two experimental groups (Figs. 2A–D). Nevertheless,
although similar blood vessel density was observed near the
limbus, the maximal distance of cell migration (Lmax) was
significantly reduced at day 11 upon sunitinib treatment (Lmax
¼ 0.82 6 0.05 in controls versus 0.62 6 0.04 in sunitinib
treated P ¼ 0.0012) (Fig. 2E). This indicates that sunitinib
inhibited blood vessel elongation at early time points. At day
17, all parameters measured were 1.8-fold decreased in
sunitinib-treated mice compared with controls (P < 0.001)
(Figs. 2A–E). Notably, the density of vessels closed to the
limbus (distance below 0.4 mm) was drastically decreased
suggesting a regression of neoformed blood vessels (Fig. 2F).
Therefore, the computer-assisted quantification reveals that
sunitinib did not influence the sprouting of new vessels from
the limbal vessels, but mainly impaired vessel elongation and
induced neoformed vessel regression. These observations are
consistent with the capacity of sunitinib to block VEGF and
PDGF receptors. Regarding lymphatic vasculature, all param-
eters measured were reduced from day 6 to day 17 (P < 0.001)
(Figs. 2G–K), suggesting a rapid inhibition of both lymphatic
vessel sprouting and elongation. This is supported, at least, by
the decreased vessel density detected upon sunitinib treat-
ment, at a distance lower than 0.4 mm from the limbus.
Sunitinib Inhibits Inflammatory Cell Recruitment
in the Cornea
We then evaluated the recruitment of inflammatory cells after
cornea cauterization in mice treated or not with sunitinib
through immunostaining directed against CD11b, which is a
general marker of inflammatory cells, or F4/80, which is more
specific of monocytic cells such as macrophages. Inflammatory
cells, especially macrophages, are indeed known to play an
important role in cornea NV, being at least a source of
prolymph/angiogenic factors.12 Through a preliminar time
course analysis of inflammatory cell recruitment in cauterized
cornea, we previously observed an early CD11bþ cell
infiltration peaking at 1 and 2 days post cauterization. F4/80þ
cells appeared later, from day 3 to day 14 post cauterization.
Double LYVE-1–CD11b and LYVE-1–F4/80 whole-mount im-
munostainings were conducted at different time points (Fig.
3B). Immunostaining quantification was performed after image
binarization (Fig. 3A). Strong CD11bþ cell infiltration was
observed in both experimental groups and quantification did
not revealed any difference between mice treated with
sunitinib and controls, 2 days or 7 days after cauterization
(Figs. 3B, 3C). An important recruitment of F4/80þ cells was
observed in control corneas after 3, 7, and 14 days. Notably, a
reduction of F4/80þ cell infiltration was already observed at
day 3 and persisted until day 14 in corneas from sunitinib-
treated mice (P < 0.001 for day 3, P < 0.05 for day 7, P < 0.01
for day 14) (Fig. 3C).
Since inflammatory cells are major producers of prolymph/
angiogenic molecules, notably VEGF-A, -C, and -D, and PlGF, we
analyzed the expression levels of these factors by RT-PCR
analysis of mRNA extracted from corneas treated or not with
sunitinib, as well as the expression level of sVEGFR-1 and
sVEGFR-2 reported as a regulator of angiogenesis and
lymphangiogenesis, respectively.2,3 At day 7, VEGF-A mRNA
levels were reduced 2-fold in sunitinib treated corneas after
cauterization (P < 0.01) (Supplementary Data S1A, S1B). VEGF-
C expression was reduced by 35% at day 21, but not modulated
at earlier time point (P < 0.01) (Supplementary Data S1C,
S1D). VEGF-D and PlGF mRNA levels were weak and no
difference was observed between the experimental groups
(Supplementary Data S1A, S1B). Identically, sVEGFR-1 and
sVEGFR-2 expressions were not affected by sunitinib treatment
(Supplementary Data S1A, S1B).
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FIGURE 1. Time course corneal lymph/angiogenesis development after thermal cauterization. (A) Blood (red) and lymphatic (green) vessels were
evidenced by whole-mount immunostaining directed against CD31 and LYVE-1, respectively, in healthy corneas (Day 0), or 3, 7, 14, 21, or 40 days
after cornea cauterization. (B) Computer-assisted quantification was based on the splitting of red and green channels to dissociate blood from
lymphatic vessels. A grid (white) was applied on each cornea picture to establish the distribution curves of capillaries around the limbal vessels (left
panel). The number of end points and branchings was determined after image binarization for blood and lymphatic vessels. The two panels on the
right illustrate, at higher magnification, end points and branchings automatically delineated by red/yellow spots. (C–F) Parameters characterizing
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Sunitinib Inhibits In Vitro Hemangiogenesis but
Not Lymphangiogenesis
We next performed in vitro aortic and lymphatic ring assays to
evaluate whether sunitinib could directly inhibit angiogenesis
and lymphangiogenesis (Fig. 4). By adding increasing concen-
trations of sunitinib (from 1–1000 nM) in the culture medium
of the aortic rings, we evidenced a strong inhibitory effect on
angiogenesis from 10 nM doses (Fig. 4D). Upon VEGF-A
stimulation of the aortic ring, the angiogenic response was
enhanced (Figs. 4A [left and middle panels], 4B, 4D). This
VEGF-A–mediated angiogenic activity was drastically reduced
by the addition of 20 nM sunitinib (Figs. 4A, 4B, 4D). In other
experiments, aortic rings were first cultured with sunitinib
during 6 days leading to a strong inhibition of endothelial cell
spreading out. When the culture medium was replaced by
sunitinib-free medium, blood capillary growth was rescued
demonstrating that the antiangiogenic effects of sunitinib does
not rely on a toxic effect on endothelial cells (data not shown).
Surprisingly, in the lymphatic ring assay, sunitinib failed to
affect lymphangiogenesis, at concentrations ranging from 1 to
1000 nM (Figs. 4A [right panels], 4C, 4E). These data suggest
that sunitinib does not exert a direct inhibitory effect on LECs.
It is worth mentioning that the impact of sunitinib in the
lymphatic ring assay has been tested in the presence of 2%
Ultroser leading to an optimal lymphangiogenic reaction.
Therefore, the failure of sunitinib to block LEC sprouting
cannot be ascribed to too low proliferation rate.
FIGURE 2. Sunitinib administration inhibits corneal neovascularization. Computer-assisted quantification of blood (A–F) and lymphatic (G–K)
vascular networks developing in the cornea after cauterization, in mice treated with sunitinib (black columns) or not (white columns). Vessel area
(A, G), branching (B, H), end point (C, I), and total length (D, J) densities, as well as maximal length of vessels (Lmax) (E), and vessel distributions
(F, K) were evaluated. *P < 0.05; **P < 0.01; ***P < 0.001.
the blood (black curve) and lymphatic (grey curve) vasculatures were normalized to the total area of the cornea (density) and include: area covered
by neoformed vessels (area density, [C]); cumulative length of the vessels (length density, [D]); number of bifurcations (branching density, [E]);
number of sprout tips (end point density, [F]). Bar represents 1 mm.
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Sunitinib Inhibits Macrophage-Induced Lymph/
Angiogenesis
To next evaluate the role of macrophages on lymph/
angiogenesis in vitro, macrophages isolated from the peritoneal
cavity were treated overnight with 20 nM sunitinib or 0.1%
DMSO. RT-PCR analyses revealed high expression levels of
VEGF-A, VEGF-C, and VEGF-D without any modulation by
sunitinib treatment (data not shown). Media conditioned by
macrophages were then used in in vitro experiments of aortic
and lymphatic ring assays (Fig. 5). The growth of aortic
explants cultured in the presence of macrophage conditioned
medium was increased as compared with controls and nearly
similar to that of explants exposed to 10 ng/mL recombinant
VEGF-A (Figs. 5A, 5B). Ring treatment with 20 nM sunitinib
induced a significant reduction of capillary outgrowth com-
pared with control rings (Figs. 5A, 5B).
In an identical manner, macrophage conditioned medium
strongly stimulated lymphatic ring growth (Figs. 5C, 5D).
While sunitinib did not reduce the growth of nonstimulated
lymphatic rings (Figs. 4A, 4C, 4E), a strong inhibition of
macrophage-induced lymphangiogenesis was observed (Figs.
FIGURE 3. Sunitinib affects F4/80þcell infiltration in inflamed corneas. (A) Computer-assisted F4/80 immunostaining (red) quantification on double
whole-mount immunostaining is performed after binarization by reporting the surface covered by F4/80þ cells to the total surface of the cornea. A
distance of 800 lm from the outer limit of the cornea was considered for quantification (right panel). (B) Double LYVE-1– CD11b (left panel) or F4/
80 (right panels) whole-mount immunostainings were performed at indicated time points, on corneas of mice treated with sunitinib (lower panels)
or not (upper panels). (C) Histograms representing quantification of CD11bþ (left panel) and F4/80þ (right panel) inflammatory cell infiltration in
inflamed corneas. Bar represents 100 lm. *P < 0.05; **P < 0.01.
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5C, 5D). Similarly, medium conditioned by macrophages
promoted proliferation and tubulogenesis of isolated LECs
(Supplementary Data S2). Sunitinib inhibited these stimulatory
effects of macrophage conditioned medium (Supplementary
Data S2). To give mechanistic insights into sunitinib action on
lymphangiogenesis, we preincubated macrophage conditioned
medium with soluble forms of VEGFR-1 or VEGFR-3 to trap
VEGF-A or VEGF-C, respectively. In these conditions, sVEGFR-1
FIGURE 4. Sunitinib inhibits in vitro angiogenesis, but not lymphangiogenesis. (A) Mouse aorta or lymphatic duct explants embedded in type I
collagen gel were cultured for 9 days in the absence (control) or presence of 20 nM sunitinib (þ sunitinib). (B, C) For quantification, grid
corresponding to successive increments at fixed intervals of explant boundary was used on binarized images and the number of microvessel grid
intersections (Ni) was quantified. (D, E) Aortic and lymphatic rings were cultured with increasing doses of sunitinib (ranging from 0–1000 nM).
Histograms represent the number of vessels (Ni) present at a distance of 0.3 mm (d¼ 0.3 mm). #, *P < 0.05; **P < 0.01; ***P < 0.001 (* compares
sunitinib-treated conditions with control and # compares VEGF-A 10 ng/mL þ sunitinib condition with VEGF-A 10 ng/mL condition).
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significantly reduced LEC proliferation while sVEGFR-3 failed
to do it, suggesting that VEGF-A is the major prolymphangio-
genic factor secreted in the macrophage conditioned medium
(Fig. 6). Concordantly, medium conditioned by macrophages
induced the phosphorylation of VEGFR-2 and two downstream
mediators (Akt and ERK1/2) as assessed by Western blot
(Supplementary Data S3). Upon sunitinib treatment, the
phosphorylation levels were drastically reduced demonstrating
the implication of VEGFR-2 pathway in the observed effects.
Moreover, conditioned medium preincubated with sVEGFR-1
induced weaker VEGFR-2 phosphorylation compared with
control macrophage conditioned medium. Conversely, prein-
cubation with sVEGFR-3 did not affect the level of phosphor-
ylated proteins (Supplementary Data S3).
DISCUSSION
Our study sheds light on the inhibition of corneal NV through
the use of a broad spectrum tyrosine kinase inhibitor. We, here,
provide evidence for combined antihemangiogenic and anti-
lymphangiogenic potential of sunitinib, of interest for ocular
disorders. Sunitinib induces a biphasic response on corneal NV
with a rapid and early inhibition of lymphangiogenesis,
followed by a blockade of hemangiogenesis. The lymphangio-
genesis inhibitory action relies at least on its capacity to reduce
inflammatory cell recruitment and to interfere with their
secreted growth factors.
Pe´rez-Santonja and colleagues previously showed that
topical sunitinib and bevacizumab administrations were able
to inhibit corneal angiogenesis in a rabbit suture-induced
model.19 However, corneal NV not only relies on hemangio-
genesis, but also on lymphangiogenesis, which has been
described as playing a major role in cornea graft rejection by
providing a route for antigens and antigen presenting cells to
regional lymph nodes.8,32 Our results provide evidence for a
strong lymphangiogenesis inhibitory potential of sunitinib.
Notably, this lymphangio-inhibitory action of sunitinib is
exerted earlier than its antihemangiogenic effects. Our results
are in line with the inhibitory effect of sunitinib on
FIGURE 5. In vitro macrophage conditioned medium-enhanced lymph/angiogenesis are reduced by sunitinib. (A, C) Aortic (A) or lymphatic (C)
rings were cultured in absence (control) or presence of 10 % macrophage conditioned medium (M/ medium) with (þ sunitinib) or without (
sunitinib) sunitinib (20 nM). (B, D) For quantification, grid corresponding to successive increments at fixed intervals of explant boundary was used
on binarized images and the number of microvessel grid intersections (Ni) was quantified on binarized images. #, *P < 0.05; ##P < 0.01 (* compares
sunitinib-treated condition with control and # compares macrophage conditioned medium þ sunitinib condition with macrophage conditioned
medium condition).
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lymphangiogenesis observed in vivo in a murine breast cancer
model.20 We also provide evidence that sunitinib, in addition to
reducing blood and lymphatic vessel growth, is able to inhibit
F4/80þ cell recruitment, but not CD11bþ cell infiltration.
Accordingly, other tyrosine kinase inhibitors, such as PTK787/
ZK222584 and ZK261991, have been reported to display
similar inhibition of macrophage recruitment in corneal NV
model.16 Reduced F4/80þ cell infiltration could result from the
inhibition of VEGF-A/VEGFR-1 pathway. Infiltrating macro-
phages represent a major source of prolymph/angiogenic
factors such as VEGF-A, -C, and -D, leading to an immune
amplification.12 It has been reported that macrophages can
also take part in the formation of lymphatic vessels by
transdifferentiating into an endothelial phenotype and incor-
porating into the lymphatic wall.33,34 The reduced F4/80þ cell
infiltration observed in our experimental model was associated
to a reduction of corneal expression of VEGF-A and -C upon
sunitinib treatment, although sunitinib treatment did not affect
their expression in isolated macrophages. This observation
suggests an indirect effect of sunitinib by interfering with F4/
80þ cell recruitment, thereby reducing the release of
prolymphangiogenic factors. In addition to its impact on
inflammatory cell recruitment, sunitinib is able to abrogate the
effects of factors secreted by macrophages as demonstrated in
the in vitro ring assays.
Surprisingly, although we observed a strong inhibition of
lymphangiogenesis in vivo upon sunitinib treatment, no
inhibitory effect was observed in vitro in the lymphatic ring
assay. Notably, upon lymphatic ring stimulation with macro-
phage conditioned medium, sunitinib reduced LEC outgrowth
to a level comparable of control conditions. This indicates that
the effect of sunitinib in vivo relies on its capacity to interfere
with prolymphangiogenic factors produced by macrophages.
This concept is further supported by the capacity of sunitinib
to block macrophage-mediated LEC proliferation and tube
formation, as well as to inhibit the activation of VEGFR-2
pathway. The blockade of macrophage-mediated mitogenic
effect by sVEGFR1 underlines the key contribution of VEGF-A
in this process. In sharp contrast, hemangiogenesis was both
inhibited in vivo and in vitro in the aortic ring assay, in basal
conditions, as well as under VEGF-A or macrophage condi-
tioned medium stimulation. It is worth mentioning that the
aortic wall contains macrophages that could contribute to the
endogenous release of angiogenic factors leading to an
angiogenic response sensitive to sunitinib treatment.35,36
Treatments targeting lymph/angiogenesis have largely been
developed in the past years and are now available to treat
different tumor types and ocular pathologies affecting poste-
rior segment of the eye.13 However, pathologic corneal NV still
lacks specific management, while being major factor of vision
impairment and strongly associated with the risk of cornea
graft rejection.7,37 Angiogenesis and lymphangiogenesis are
intricate processes in cornea NV and share common regulatory
pathways.9 We provide data showing strong combined
inhibition of corneal angiogenesis and lymphangiogenesis by
sunitinib, suggesting a potential interest for corneal NV
treatment. Importantly, a transient in vivo administration of
sunitinib (during the first 6 days following cornea cauteriza-
tion) was not sufficient to efficiently repress corneal NV.
Similarly, no inhibitory effect of a transient sunitinib treatment
was observed in vitro in the aortic ring assay. These data
suggest a rapid regrowth of blood vessels after treatment
withdrawal. This observation implies a sustained sunitinib
exposure to treat ocular disorders. Previous studies demon-
strated that corneal NV inhibition through VEGF-A blockade
promoted cornea graft survival in murine model.15,38 Not only
has VEGF-A been implicated in corneal NV, but also PDGF
through its action on vessel stabilization,39 as well as VEGF-C
and -D that activate lymphangiogenesis.40–42 A combined
inhibition of VEGFR-2 and PDGFR in blocking corneal
angiogenesis has proven more efficient than single VEGF-A
pathway blockade.43,44 The use of multi-target tyrosine kinase
inhibitors also provides higher survival rate for cornea
engraftment.16 We, herein, provide evidence that the use of a
multi-potent tyrosine kinase inhibitor such as sunitinib, both
targeting effectors of hemangiogenesis and of lymphangio-
genesis, could provide higher efficiency in the treatment of
corneal NV.
In conclusion, our study provides evidence for strong
antilymph/angiogenic potential of sunitinib in inflammation-
induced corneal NV, acting through the inhibition of F4/80þ
cell recruitment in inflamed corneas, thereby decreasing the
secretion of VEGF-A and -C. The use of such a multi-target
tyrosine kinase inhibitor could be considered for treatment in
order to prevent cornea vascularization occurring in inflam-
matory conditions and to increase cornea graft survival in case
of keratoplasty.
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